Find → Understand → Decide
Erlotinib
Discovery priority: LOW · POSSIBLE / INVESTIGATE
Discovery priority ≠ investment recommendation. These are observation labels, not verified canonical products. Buyer qualification: UNKNOWN.
Why investigate?
Why stranded (event context): efficacy failure; inadequate public evidence
Why now: Historical lead requires current reconfirmation; no fresh transaction catalyst established
Company/trial failed before biology? UNKNOWN
Biology implicated: UNCLEAR · Failure context: DRUG/BIOLOGY
MODEL INFERENCE · LOW confidence. Explicit asset-linked program event or documented experimental trial arm, stop scope, dated recency and biological cautions; no publication count or buyer-gate input.
Current control: UNKNOWN · Restart: UNKNOWN · Development reuse: UNKNOWN
Next diligence: Confirm present program status and exact product identity, then trace scoped rights/data/CMC and review arm-level human outcomes.
Existing buyer gates
Human Signal: UNKNOWN
Cheap Truth: UNKNOWN
Clean Rights: UNKNOWN
Market Pull: UNKNOWN
No event or publication count supplies missing gate evidence. Existing reviewed opportunities remain in their original records.
Evidence timeline
2016-05-13 · trial:NCT01320501
Registry update date, not proven program-stop date
SOURCE TEXT · Exact source
Difficulty in enrolling patients
Trial reason is not attributed to every intervention; comparator/combination context needs review.
Interpretation: inadequate public evidence · AUTO_INFERRED · MEDIUM
Provenance and retrieval scope
{
"hash": "e78b2aad531cde96e53a6499cc37b0f49988decf82ec30a17fc546dd8b9e63fb",
"metadata": {
"complete": false,
"content_hash": "38a1f6b0acab83e32f1bc4be6780a423f51adefad10b1134fa1db1296649450e",
"failed": false,
"last_checked": 1790026984.0751398,
"last_success": 1790026984.0751398,
"live_verified": true,
"scope": "AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2000-01-01,2014-12-31] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)"
},
"path": "protocolSection.armsInterventionsModule.interventions",
"raw_hash": "38a1f6b0acab83e32f1bc4be6780a423f51adefad10b1134fa1db1296649450e",
"raw_path": "research/obz7_sources/38a1f6b0acab83e32f1bc4be6780a423f51adefad10b1134fa1db1296649450e.json",
"request_params": {
"countTotal": "true",
"format": "json",
"pageSize": 100,
"query.term": "AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2000-01-01,2014-12-31] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)",
"sort": "LastUpdatePostDate:desc"
},
"request_url": "https://clinicaltrials.gov/api/v2/studies",
"type": "clinicaltrials",
"url": "https://clinicaltrials.gov/study/NCT01320501"
}2026-07-07 · trial:NCT00640978
Registry update date, not proven program-stop date
SOURCE TEXT · Exact source
Significant Adverse Effects - Futility
Trial reason is not attributed to every intervention; comparator/combination context needs review.
Interpretation: efficacy failure · AUTO_INFERRED · MEDIUM
Provenance and retrieval scope
{
"hash": "5154e159156bdd88a9b3285401e52785db423f231c621a32254ca62b76a78302",
"metadata": {
"complete": false,
"content_hash": "0e3eac157b6bfeb4b79d12ac63d9568e02e2be5b2c97d85cda2cc0e3aea17bb7",
"failed": false,
"last_checked": 1790026980.1182604,
"last_success": 1790026980.1182604,
"live_verified": true,
"scope": "AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2000-01-01,2014-12-31] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)"
},
"path": "protocolSection.armsInterventionsModule.interventions",
"raw_hash": "0e3eac157b6bfeb4b79d12ac63d9568e02e2be5b2c97d85cda2cc0e3aea17bb7",
"raw_path": "research/obz7_sources/0e3eac157b6bfeb4b79d12ac63d9568e02e2be5b2c97d85cda2cc0e3aea17bb7.json",
"request_params": {
"countTotal": "true",
"format": "json",
"pageSize": 100,
"query.term": "AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2000-01-01,2014-12-31] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)",
"sort": "LastUpdatePostDate:desc"
},
"request_url": "https://clinicaltrials.gov/api/v2/studies",
"type": "clinicaltrials",
"url": "https://clinicaltrials.gov/study/NCT00640978"
}Freshness is claim-specific
Fetching an old filing today does not establish current ownership or program status.
pipeline · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
sec · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
rights · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
contact · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
patent_assignment · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
clinicaltrials · STALE · AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2000-01-01,2014-12-31] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL) · checked 2026-09-21T21:43:00.118260+00:00
clinicaltrials · STALE · AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2000-01-01,2014-12-31] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL) · checked 2026-09-21T21:43:04.075140+00:00
Registry observations (4)
NCT00640978 · TERMINATED · PHASE2 · Pancreatic Cancer · Trial sponsor M.D. Anderson Cancer Center
Reported aliases: Erlotinib Hydrochloride; OSI-774; Tarceva. Identity, treatment role and exposure require review.
NCT01320501 · SUSPENDED · PHASE4 · Non-small Cell Lung Cancer Metastatic · Trial sponsor National Guard Health Affairs
Reported aliases: None. Identity, treatment role and exposure require review.
NCT01562028 · COMPLETED · PHASE2 · Lung Cancer · Trial sponsor ETOP IBCSG Partners Foundation
Reported aliases: Tarceva (R) (Roche). Identity, treatment role and exposure require review.
NCT01652469 · COMPLETED · PHASE3 · Carcinoma, Non-Small-Cell Lung · Trial sponsor ETOP IBCSG Partners Foundation
Reported aliases: Tarceva (Roche). Identity, treatment role and exposure require review.